The Peer Reviewed Medical Research Program (PRMRP), established by the Department Of Defense-Congressionally Directed Medical Research Programs in 1999, has supported research across the full range of science and medicine, with an underlying goal of enhancing the health, care, and well-being of military Service members, Veterans, retirees, and their family members.
The PRMRP is committed to supporting research that has the potential to profoundly impact the development and implementation of medical devices, drugs, and clinical guidance that will enhance the precision and efficacy of prevention, diagnosis, and treatment across a wide range of disciplines including autoimmune diseases and immunology, cardiovascular health, endocrine health and metabolism, environmental health, infectious diseases, internal medicine, neurological and psychological health, orthopedic and regenerative medicine, and respiratory health and injury.
Two opportunities are now open for applications
Pre-Application (Letter of Intent) Deadline: June 9, 2025 5:00 p.m. Eastern Time
Application Deadline: July 21, 2025 11:59 p.m. Eastern Time
Technology/Therapeutic Development Award
Summary: The fiscal year 2025 PRMRP Technology/Therapeutic Development Award (TTDA) is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the FY25 PRMRP topic areas (which include multiple sclerosis) and one of the FY25 PRMRP strategic goals. Products in development should be responsive to the health care needs of military Service Members, Veterans, and their Families.
For more information and to apply
Summary: The fiscal year 2025 PRMRP Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of a disease or condition addressed in one of the congressionally directed FY25 PRMRP topic areas (which include multiple sclerosis) and FY25 PRMRP strategic goals.
